Ranibizumab

Common brands: Lucentis, Susvimo, Avastin, Eylea, Ecotrin

Top reporter: Genentech, Inc.

Vascular Endothelial Growth Factor Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Platelet Aggregation Inhibitor [EPC]HMG-CoA Reductase Inhibitor [EPC]Insulin Analog [EPC]

26,273

Total Reports

7,764

Serious Reports

5,088

Death Reports

Reported Reactions

Death Report Ratio: High (19.37%)

Patient Demographics

Male

9,986

Female

12,815

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ranibizumab.

#	Reaction	Reports	% of Total
1	DEATH	3,794	13.8%
2	VISUAL ACUITY REDUCED	2,891	10.5%
3	OFF LABEL USE	1,697	6.2%
4	VISUAL IMPAIRMENT	1,629	5.9%
5	CEREBROVASCULAR ACCIDENT	1,237	4.5%
6	DRUG INEFFECTIVE	1,202	4.4%
7	NO ADVERSE EVENT	1,045	3.8%
8	BLINDNESS	1,043	3.8%
9	EYE HAEMORRHAGE	1,043	3.8%
10	VISION BLURRED	1,031	3.8%
11	EYE PAIN	956	3.5%
12	RETINAL HAEMORRHAGE	792	2.9%
13	ENDOPHTHALMITIS	728	2.7%
14	MYOCARDIAL INFARCTION	689	2.5%
15	CATARACT	683	2.5%
16	VITREOUS FLOATERS	619	2.3%
17	FALL	590	2.1%
18	MALAISE	584	2.1%
19	MACULAR OEDEMA	576	2.1%
20	HEADACHE	488	1.8%
21	BLINDNESS UNILATERAL	463	1.7%
22	OCULAR HYPERAEMIA	450	1.6%
23	VITREOUS HAEMORRHAGE	449	1.6%
24	AGE-RELATED MACULAR DEGENERATION	445	1.6%
25	DISEASE PROGRESSION	424	1.5%
26	EYE DISORDER	419	1.5%
27	INTRAOCULAR PRESSURE INCREASED	410	1.5%
28	RETINAL OEDEMA	367	1.3%
29	HYPERTENSION	358	1.3%
30	CHOROIDAL NEOVASCULARISATION	357	1.3%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.